Tylenol in the Spotlight: Pregnancy, Autism, and Evolving Guidance on Acetaminophen use

Why Tylenol is Trending This Week

Acetaminophen, widely known under the brand name Tylenol, has become a focal point of public and professional debate after the U.S. Food and Drug Administration (FDA) announced on September 22, 2025 that it will begin updating product labels to include warnings about a possible association between prenatal use and neurodevelopmental outcomes such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). The FDA simultaneously issued a Notice to Physicians, noting that some epidemiologic studies suggest increased risk when acetaminophen is used chronically or throughout gestation, while occasional use remains less concerning.
The story gained traction because former President Donald Trump and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. urged pregnant women to “avoid Tylenol” in public remarks, amplifying concerns in the media. These statements prompted immediate responses from professional bodies and global regulators. The European Medicines Agency (EMA) and the World Health Organization (WHO) both reaffirmed that acetaminophen remains safe when used as recommended during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) issued a statement emphasizing that high-quality studies have not established causation between prenatal acetaminophen use and ASD or ADHD.

Acetaminophen and Pregnancy: Evidence to Date

Acetaminophen has long been considered the analgesic and antipyretic of choice during pregnancy, largely because alternatives such as nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin carry clearer risks in later trimesters. Recent data, however, have sparked renewed scrutiny. A 2024 JAMA cohort study using sibling comparisons found that initial associations between maternal acetaminophen use and later ASD/ADHD risk were nullified when controlling for familial factors, suggesting confounding rather than causation. A Mount Sinai systematic review in 2025 using the Navigation Guide framework reported that higher-quality studies more often observed associations between prenatal acetaminophen exposure and neurodevelopmental outcomes, though causality remains uncertain. The FDA’s recent physician notice highlights that the strongest signals arise in women reporting frequent, high-dose, or long-term acetaminophen use across multiple trimesters. Importantly, residual confounding, such as maternal fever, infection, or other underlying conditions, continues to complicate interpretation.

Clinical Guidance for Physicians

For clinicians, the task is balancing emerging observational signals with well-established maternal benefits of pain and fever control. Current consensus across major organizations includes the following. The FDA has confirmed label changes are forthcoming; physicians should stay updated and contextualize the evolving evidence with patients. ACOG states that acetaminophen remains appropriate in pregnancy when clinically indicated, used at the lowest effective dose for the shortest time. The Society for Maternal-Fetal Medicine (SMFM) has emphasized that causality is unproven and cautioned against fear-driven avoidance that could leave febrile or painful conditions untreated. The WHO and EMA have reiterated that no new restrictions are warranted and acetaminophen remains a recommended first-line therapy in pregnancy. Counseling should stress that occasional short-term use is unlikely to confer risk, while repeated or prolonged exposure should be minimized when possible.

Bottom Line

Tylenol is trending this week because of new FDA label action and highly publicized political statements linking prenatal acetaminophen use to autism and ADHD. While the FDA is moving toward precautionary labeling, professional societies and international regulators continue to view acetaminophen as a safe option in pregnancy when used appropriately. Physicians should anticipate increased patient concern, provide context that current evidence does not prove causation, and emphasize judicious, short-term use while monitoring ongoing research.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.